New Glioblastoma Treatment Combination Shows Promise
A new dual-compound approach suppresses tumor metabolism in laboratory models of this aggressive cancer.
Updated on Oct. 16, 2026 in Cancer
Researchers have identified two novel compounds, EPIC-1027 and EPIC-1042, that show promise in treating glioblastoma by suppressing cellular energy production. This combination therapy reduced tumor growth and extended survival in laboratory mouse models.
Why it matters
Current treatments like temozolomide for glioblastoma are often limited by tumor resistance mechanisms, creating a critical need for new therapeutic approaches. This research explores a potential new pathway to disrupt the metabolism of brain tumor cells.
This preclinical study utilized proteomics and metabolic flux analysis to evaluate the efficacy of combining two novel compounds, EPIC-1027 and EPIC-1042. The treatment successfully inhibited cell proliferation in vitro and attenuated tumor growth in orthotopic glioblastoma mouse models.
The details
The treatment works by targeting the metabolic flexibility of glioblastoma cells, specifically by reducing the abundance of respiratory chain complex proteins. This leads to the suppression of both glycolytic activity and oxidative phosphorylation, effectively starving the cancer cells of energy. Additionally, the compounds promote p62-dependent protein degradation, leading to apoptosis in an MGMT-independent manner, which may help bypass resistance to traditional chemotherapy.
Timeline
- 2026-10-16
Results of the study were published.
Health Landscape
Glioblastoma remains one of the most aggressive and difficult cancers to treat, largely due to resistance against standard therapies. This research moves the field toward targeting the fundamental metabolic processes that support tumor survival and proliferation.
Because these findings are limited to laboratory and animal studies, they do not yet translate to clinical practice or treatment changes. Patients managing glioblastoma should continue to discuss current standard-of-care options and relevant clinical trial enrollment with their oncologist.
The takeaway
This discovery highlights how targeting cancer metabolism can disrupt the growth of aggressive brain tumors in a laboratory setting. Keep following updates on glioblastoma research to see if these compounds progress to human safety and efficacy trials.
Further reading
For more information on the evolving standards of care, visit Cancer.
Source note: This article includes information reported by Nature.
